Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-05-14

Apellis Pharmaceuticals, Inc. (APLS)

CEO Cedric Francois was paid $10,957,451 in fiscal year 2024, ↑ up 5.6% from fiscal year 2023, the 38th percentile of its disclosed peer group (SEC filing 0000950170-25-056966 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$10,957,451 ↑
Cedric Francois total, FY2024
38th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
94.8%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Cedric Francois (President & Chief Executive Officer), FY2024 total compensation $10,957,451 (base salary $793,193) [exec_comp, SEC accession 0000950170-25-056966, filed 2025-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Cedric Francois$793,193$580,736$4,779,832$4,787,768$0$0$15,922$10,957,451
President & Chief Executive Officer
Caroline Baumal610,386279,0261,687,0041,689,79000140,9224,407,128
Chief Medical Officer
Adam Townsend542,732249,5351,574,4921,577,1220012,1723,956,053
Chief Commercial Officer
Timothy Sullivan530,963242,7301,574,4921,577,1220023,7683,949,075
Chief Financial Officer
David Watson513,078211,1071,574,4921,577,1220015,9223,891,721
General Counsel

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Cedric Francois$10,957,451$10,373,049$9,203,556↑ +584,402
Caroline Baumal4,407,1284,430,459—↓ −23,331
Adam Townsend3,956,0533,714,2463,096,029↑ +241,807
Timothy Sullivan3,949,0753,737,2353,546,148↑ +211,840
David Watson3,891,7214,885,8893,069,773↓ −994,168

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Apellis Pharmaceuticals, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper APLS reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Apellis Pharmaceuticals, Inc. Peer Teardown Report

$10,957,451 Cedric Francois total, FY2024

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of May 14, 2026 · Source: 0000950170-25-056966 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for APLS

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
APLSon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order APLS

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against APLS
39 companies name APLS as a compensation peer

Each company listed discloses APLS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named APLS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the Apellis Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
A. Sinclair DunlopIndependent Director$477,465
Alec MachielsIndependent Director$492,465
Gerald ChanIndependent Director$498,715
Paul FonteyneIndependent Director$487,465
Stephanie Monaghan O'BrienDirector$484,965
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Cedric FrancoisDirector2026-05-14D195,952——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D36,047——CommonForm 4 ↗
Craig WheelerDirector2026-05-14D7,961——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D30,845——Derivative, Class A CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14A36,606——CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D9,754——CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14A24,284——CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14A22,610——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14A143,750——CommonForm 4 ↗
Gerald ChanDirector2026-05-14D17,580——Derivative, Class A CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D41,250——CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D110,000——Derivative, Class A CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14A12,920——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14A30,620——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D41,250——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D71,492——Common, indirectForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D140,945——CommonForm 4 ↗
Alec MachielsDirector2026-05-14D384,989——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D30,000——Derivative, Class A CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D27,224——Derivative, Class A CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D82,500——Derivative, Class A CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D4,909——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D18,303——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D41,250——CommonForm 4 ↗
Keli WalbertDirector2026-05-14D14,684——Derivative, Class A CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D45,000——Derivative, Class A CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D70,125——Derivative, Class A CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D82,500——Derivative, Class A CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D11,874——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D58,140——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14A58,140——CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14D9,444——CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D32,072——CommonForm 4 ↗
Caroline BaumalChief Medical Officer2026-05-14D41,250——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D206,250——Derivative, Class A CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D170,400——Derivative, Class A CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D273,312——Derivative, Class A CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D45,000——Derivative, Class A CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D6,001——CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D55,986——CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D10,000——CommonForm 4 ↗
Kelley BoucherChief People Officer2026-05-14D30,476——CommonForm 4 ↗
Kelley BoucherChief People Officer2026-05-14D30,146——CommonForm 4 ↗
Kelley BoucherChief People Officer2026-05-14A15,073——CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D27,600——Derivative, Class A CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D3,062——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D24,666——Derivative, Class A CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D6,952——Derivative, Class A CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D18,750——Derivative, Class A CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D14,799——Derivative, Class A CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D21,381——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D8,482——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D36,606——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14A18,303——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D36,606——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D19,006——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14A19,006——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14A41,250——CommonForm 4 ↗
Mark Jeffrey DeLongChief Business & Strat Officer2026-05-14D114,591——CommonForm 4 ↗
Keli WalbertDirector2026-05-14D15,388——Derivative, Class A CommonForm 4 ↗
Keli WalbertDirector2026-05-14D7,297——CommonForm 4 ↗
Keli WalbertDirector2026-05-14D17,051——CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D28,367——Derivative, Class A CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D35,472——Derivative, Class A CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D45,000——Derivative, Class A CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D50,974——Derivative, Class A CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D115,281——Derivative, Class A CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D82,500——Derivative, Class A CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D45,220——CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D27,320——CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D45,220——CommonForm 4 ↗
Nur NicholsonChief Technical Officer2026-05-14D22,610——CommonForm 4 ↗
Gerald ChanDirector2026-05-14D27,600——Derivative, Class A CommonForm 4 ↗
Gerald ChanDirector2026-05-14D3,062——CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D82,500——Derivative, Class A CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D25,840——CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D4,909——CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D25,840——CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D12,920——CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D41,250——CommonForm 4 ↗
Alec MachielsDirector2026-05-14D3,544——CommonForm 4 ↗
Alec MachielsDirector2026-05-14D11,950——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D43,183——Derivative, Class A CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D60,242——Derivative, Class A CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D23,958——Derivative, Class A CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D84,946——Derivative, Class A CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D232,903——Derivative, Class A CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D58,140——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D34,447——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D6,872——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D29,070——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14A29,070——CommonForm 4 ↗
Timothy SullivanChief Financial Officer2026-05-14D30,620——CommonForm 4 ↗
Paul FonteyneDirector2026-05-14D8,554——Derivative, Class A CommonForm 4 ↗
Paul FonteyneDirector2026-05-14D14,684——Derivative, Class A CommonForm 4 ↗
Paul FonteyneDirector2026-05-14D3,877——CommonForm 4 ↗
Paul FonteyneDirector2026-05-14D7,961——CommonForm 4 ↗
Paul FonteyneDirector2026-05-14D30,666——CommonForm 4 ↗
Leslie MeltzerChief Research and Development2026-05-14D92,592——Derivative, Class A CommonForm 4 ↗
Leslie MeltzerChief Research and Development2026-05-14D45,220——CommonForm 4 ↗
Leslie MeltzerChief Research and Development2026-05-14D45,220——CommonForm 4 ↗
Mikael DolstenDirector2026-05-14D24,135——Derivative, Class A CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14D12,086——Derivative, Class A CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14D20,853——Derivative, Class A CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14D16,150——CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14D4,156——CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14D2,406——CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14D8,075——CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14A8,075——CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14A16,150——CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14D5,625——CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14A5,625——CommonForm 4 ↗
A. Sinclair DunlopDirector2026-05-14D7,961——CommonForm 4 ↗
Craig WheelerDirector2026-05-14D24,444——CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D9,805——Derivative, Class A CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D56,250——Derivative, Class A CommonForm 4 ↗
Caroline BaumalChief Medical Officer2026-05-14D8,888——CommonForm 4 ↗
Gerald ChanDirector2026-05-14D8,554——Derivative, Class A CommonForm 4 ↗
Gerald ChanDirector2026-05-14D14,684——Derivative, Class A CommonForm 4 ↗
Pascal DeschateletsChief Scientific Officer2026-05-14D1,177,222——CommonForm 4 ↗
Alec MachielsDirector2026-05-14D5,748——Derivative, Class A CommonForm 4 ↗
Alec MachielsDirector2026-05-14D121,894——Derivative, Class A CommonForm 4 ↗
Leslie MeltzerChief Research and Development2026-05-14D61,804——CommonForm 4 ↗
Caroline BaumalChief Medical Officer2026-05-14D86,525——CommonForm 4 ↗
Kelley BoucherChief People Officer2026-05-14D45,766——Derivative, Class A CommonForm 4 ↗
Alec MachielsDirector2026-05-14D3,062——CommonForm 4 ↗
Gerald ChanDirector2026-05-14D121,894——Derivative, Class A CommonForm 4 ↗
James George ChopasVP/Chief Accounting Officer2026-05-14D8,394——CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D5,748——Derivative, Class A CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D8,554——Derivative, Class A CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D11,199——Derivative, Class A CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D14,684——Derivative, Class A CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D121,894——Derivative, Class A CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D17,580——Derivative, Class A CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D3,544——CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D3,877——CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D7,961——CommonForm 4 ↗
Caroline BaumalChief Medical Officer2026-05-14D26,396——CommonForm 4 ↗
Caroline BaumalChief Medical Officer2026-05-14D37,000——Derivative, Class A CommonForm 4 ↗
Caroline BaumalChief Medical Officer2026-05-14D49,000——Derivative, Class A CommonForm 4 ↗
Caroline BaumalChief Medical Officer2026-05-14D29,696——CommonForm 4 ↗
Caroline BaumalChief Medical Officer2026-05-14D12,723——CommonForm 4 ↗
Caroline BaumalChief Medical Officer2026-05-14A26,396——CommonForm 4 ↗
Alec MachielsDirector2026-05-14D27,600——Derivative, Class A CommonForm 4 ↗
Alec MachielsDirector2026-05-14D7,441——Derivative, Class A CommonForm 4 ↗
Alec MachielsDirector2026-05-14D8,554——Derivative, Class A CommonForm 4 ↗
Alec MachielsDirector2026-05-14D11,199——Derivative, Class A CommonForm 4 ↗
Alec MachielsDirector2026-05-14D27,600——Derivative, Class A CommonForm 4 ↗
Alec MachielsDirector2026-05-14D17,580——Derivative, Class A CommonForm 4 ↗
Alec MachielsDirector2026-05-14D7,961——CommonForm 4 ↗
Alec MachielsDirector2026-05-14D5,744——CommonForm 4 ↗
Keli WalbertDirector2026-05-14D664——CommonForm 4 ↗
Keli WalbertDirector2026-05-14D8,332——CommonForm 4 ↗
Alec MachielsDirector2026-05-14D250,000——CommonForm 4 ↗
A. Sinclair DunlopDirector2026-05-14D11,199——Derivative, Class A CommonForm 4 ↗
A. Sinclair DunlopDirector2026-05-14D3,544——CommonForm 4 ↗
A. Sinclair DunlopDirector2026-05-14D5,744——CommonForm 4 ↗
A. Sinclair DunlopDirector2026-05-14D3,062——CommonForm 4 ↗
A. Sinclair DunlopDirector2026-05-14D161,567——CommonForm 4 ↗
Paul FonteyneDirector2026-05-14D11,199——Derivative, Class A CommonForm 4 ↗
Paul FonteyneDirector2026-05-14D3,544——CommonForm 4 ↗
Stephanie Monaghan O'BrienDirector2026-05-14D5,750——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D150,000——Derivative, Class A CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14A195,952——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D300,000——Common, indirectForm 4 ↗
Cedric FrancoisDirector2026-05-14D472,065——Common, indirectForm 4 ↗
Cedric FrancoisDirector2026-05-14D372,815——Common, indirectForm 4 ↗
Cedric FrancoisDirector2026-05-14D104,834——Derivative, Class A CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D131,093——Derivative, Class A CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D287,500——Derivative, Class A CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D100,538——Derivative, Class A CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D97,997——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D20,862——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D195,952——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D97,976——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14A87,108——CommonForm 4 ↗
Cedric FrancoisDirector2026-05-14D234,411——Common, indirectForm 4 ↗
David WatsonGeneral Counsel2026-05-14D14,000——Derivative, Class A CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D34,533——Derivative, Class A CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D37,708——Derivative, Class A CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D38,250——Derivative, Class A CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D82,500——Derivative, Class A CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D7,363——CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D11,874——CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14D55,986——CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14A55,986——CommonForm 4 ↗
David WatsonGeneral Counsel2026-05-14A27,993——Common, indirectForm 4 ↗
David WatsonGeneral Counsel2026-05-14A28,508——Common, indirectForm 4 ↗
David WatsonGeneral Counsel2026-05-14D41,250——Common, indirectForm 4 ↗
David WatsonGeneral Counsel2026-05-14A41,250——Common, indirectForm 4 ↗
Gerald ChanDirector2026-05-14D3,877——CommonForm 4 ↗
Gerald ChanDirector2026-05-14D7,961——CommonForm 4 ↗
Gerald ChanDirector2026-05-14D5,744——CommonForm 4 ↗
Gerald ChanDirector2026-05-14D5,748——Derivative, Class A CommonForm 4 ↗
Gerald ChanDirector2026-05-14D11,199——Derivative, Class A CommonForm 4 ↗
Craig WheelerDirector2026-05-14D14,684——Derivative, Class A CommonForm 4 ↗
Craig WheelerDirector2026-05-14D28,195——Derivative, Class A CommonForm 4 ↗
Craig WheelerDirector2026-05-14D15,110——CommonForm 4 ↗
Gerald ChanDirector2026-05-14D7,441——Derivative, Class A CommonForm 4 ↗
Kelley BoucherChief People Officer2026-05-14D32,976——Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Timothy SullivanOPTION2024-01-16——34,533—$1,577,122
David WatsonOPTION2024-01-16——34,533—1,577,122
Caroline BaumalRSU2024-01-16——25,445—1,687,004
David WatsonRSU2024-01-16——23,748—1,574,492
Cedric FrancoisOPTION2024-01-16——104,834—4,787,768
Adam TownsendOPTION2024-01-16——34,533—1,577,122
Cedric FrancoisRSU2024-01-16——72,094—4,779,832
Timothy SullivanRSU2024-01-16——23,748—1,574,492
Adam TownsendRSU2024-01-16——23,748—1,574,492
Caroline BaumalOPTION2024-01-16——37,000—1,689,790
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Timothy Sullivan$1,574,492$0$1,577,1220.0%
David Watson1,574,49201,577,1220.0%
Caroline Baumal1,687,00401,689,7900.0%
Cedric Francois4,779,83204,787,7680.0%
Adam Townsend1,574,49201,577,1220.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Caroline BaumalOption25,52150.28—
David WatsonRSU17,969—573,391
Caroline BaumalRSU26,662—850,784
Timothy SullivanRSU20,616—657,857
Cedric FrancoisRSU72,094—2,300,520
Cedric FrancoisRSU62,586—1,997,119
Cedric FrancoisRSU60,076—1,917,025
David WatsonRSU40,092—1,279,336
Caroline BaumalRSU25,445—811,950
Timothy SullivanRSU23,748—757,799
David WatsonRSU23,748—757,799
Adam TownsendRSU23,748—757,799
Timothy SullivanRSU21,236—677,641
Adam TownsendRSU20,616—657,857
Adam TownsendRSU17,969—573,391
Cedric FrancoisRSU6,250—199,438
Timothy SullivanRSU1,875—59,831
David WatsonRSU1,875—59,831
Adam TownsendRSU1,875—59,831
Cedric FrancoisOption104,83466.3—
Cedric FrancoisOption68,27852.66—
Cedric FrancoisOption46,15035.46—
Cedric FrancoisOption3,12544.9—
Timothy SullivanOption34,53366.3—
Timothy SullivanOption22,49252.66—
Timothy SullivanOption16,31735.46—
Timothy SullivanOption93844.9—
Caroline BaumalOption37,00066.3—
David WatsonOption34,53366.3—
David WatsonOption19,64052.66—
David WatsonOption13,80835.46—
David WatsonOption93844.9—
Adam TownsendOption34,53366.3—
Adam TownsendOption22,49252.66—
Adam TownsendOption13,80835.46—
Adam TownsendOption93844.9—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation program is designed to attract, motivate and retain qualified and talented executives, motivating them to achieve our business goals and rewarding them for superior short- and long-term performance. The program aligns the interests of our executive officers with those of our stockholders to increase stockholder value, with a significant portion of compensation being variable and at risk, tied to stock price performance or achievement of pre-set performance objectives.

CEO STI target (% of salary)80%
CEO LTI target (% of salary)—
Independent consultantPay Governance
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-0375,901,9204,167,10359,86094.8%Passed
20242024-06-0593,573,35710,540,01044,70889.88%Passed
20232023-06-0194,979,5796,659,652546,45793.45%Passed
20222022-06-0184,569,7401,617,36413,08198.12%Passed
20212021-06-0158,558,2811,654,65412,92997.25%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-06-0394.8%a
20242024-06-0589.88%b
20232023-06-0193.45%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Gerald ChanIndependent$98,750$199,992$199,973——$498,715
Alec MachielsIndependent · Audit (Chair) · Compensation · Compliance92,500199,992199,973——492,465
Paul FonteyneIndependent · Audit87,500199,992199,973——487,465
Stephanie Monaghan O'BrienNot independent85,000199,992199,973——484,965
A. Sinclair DunlopIndependent · Audit · Nominating and Corporate Governance77,500199,992199,973——477,465
Cedric FrancoisEmployee director—————0
Craig WheelerIndependent · Newly elected——————
Keli WalbertIndependent · Compensation · Compliance · Nominating & Corporate Governance · Newly elected——————
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$400,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)12,500 / 10,000 / 7,500
Stock ownership guideline$150,000
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$441,250
Equity awards (grant-date value)$999,960
All other compensation$0
Total cost of the board$1,441,210

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Apellis Pharmaceuticals, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Apellis Pharmaceuticals, Inc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1PTC Therapeutics2025Matthew Klein$958,500$16,593,800$4,399,760$1,294,000$23,266,326
2Madrigal Pharmaceuticals, Inc.2025Bill Sibold918,53112,297,8504,537,1461,438,81419,206,341
3Corcept Therapeutics Incorporated2025Joseph Belanoff1,182,333012,907,718015,303,551
4Insmed Incorporated2025William Lewis854,5502,999,9409,000,0331,495,46314,467,393
5Blueprint Medicines Corporation2024Kathryn Haviland821,3637,472,4804,315,144854,21713,477,004
6Neurocrine Biosciences2025Kyle Gano920,0005,750,0235,750,006013,448,935
7Ionis Pharmaceuticals2025Brett Monia1,051,7768,444,8381,438,105013,350,777
8Biocryst Pharmaceuticals, Inc2025Jon Stonehouse728,466011,132,4581,052,63312,951,082
9Apellis Pharmaceuticals, Inc.2024Cedric Francois793,1934,779,8324,787,768010,957,451
10Axsome Therapeutics, Inc.2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
11Intra-Cellular Therapies, Inc.2023Sharon Mates891,6537,749,9840010,086,413
12Amicus Therapeutics, Inc.2024Bradley Campbell767,3084,990,3652,105,62708,526,943
13ACADIA Pharmaceuticals2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
14Alkermes plc2025Richard Pops1,250,76905,020,8121,626,0007,915,081

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Apellis Pharmaceuticals, Inc.90.74%RSU 50 · PSU 50not disclosedPay Governance
ACADIA Pharmaceuticals110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Alkermes plc130%PRSU 53 · RSU 24 · Option 23Yes — Relative Total Shareholder Return (TSR)Alpine Rewards LLC
Amicus Therapeutics, Inc.not disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
Axsome Therapeutics, Inc.150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
Biocryst Pharmaceuticals, Incnot disclosednot disclosednot disclosedAon
Blueprint Medicines Corporation130%RSU 37 · Options 32 · PSU 31Yes — Relative Total Stockholder Return (rTSR)Aon
Corcept Therapeutics IncorporatedDr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%%Stock Options 100not disclosednot disclosed
Insmed Incorporated175%Options 75 · RSU 25NoWillis Towers Watson (WTW)
Intra-Cellular Therapies, Inc.not disclosedRSU 75 · PRSU 25Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology IndexAon Consulting, Inc.
Ionis Pharmaceuticalsnot disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Madrigal Pharmaceuticals, Inc.195%PSU 33 · RSU 33 · Options 33Yes — Relative TSR vs Nasdaq Biotechnology IndexCompensia
Neurocrine Biosciences105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
PTC Therapeuticsnot disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Apellis Pharmaceuticals, Inc. in fiscal 2024?
As disclosed, Cedric Francois (President & Chief Executive Officer) was the highest-paid executive at Apellis Pharmaceuticals, Inc. in fiscal 2024, with total compensation of $10,957,451.
How does Apellis Pharmaceuticals, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Cedric Francois's total compensation ranked at the 38th percentile of Apellis Pharmaceuticals, Inc.'s disclosed peer group.
How did shareholders vote on Apellis Pharmaceuticals, Inc.'s executive compensation?
As disclosed, 94.8% of shareholders supported Apellis Pharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Apellis Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Apellis Pharmaceuticals, Inc. reported total board compensation of $1,441,210 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Cedric FrancoisDEF 14A2025-04-230000950170-25-056966Section “Executive Compensation”. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
2Section 01, Caroline BaumalDEF 14A2025-04-230000950170-25-056966Section “Executive Compensation”. As printed: 4,407,128. Filing ↗machine: r8 · c25 · span 1003912–1003921
3Section 01, Adam TownsendDEF 14A2025-04-230000950170-25-056966Section “Executive Compensation”. As printed: 3,956,053. Filing ↗machine: r13 · c25 · span 1047537–1047546
4Section 01, Timothy SullivanDEF 14A2025-04-230000950170-25-056966Section “Executive Compensation”. As printed: 3,949,075. Filing ↗machine: r5 · c25 · span 977730–977739
5Section 01, David WatsonDEF 14A2025-04-230000950170-25-056966Section “Executive Compensation”. As printed: 3,891,721. Filing ↗machine: r10 · c25 · span 1021390–1021399
6Section 03, Timothy Sullivan OPTIONDEF 14A2025-04-230000950170-25-056966Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r4 · c3 · span 846013–846019
7Section 03, David Watson OPTIONDEF 14A2025-04-230000950170-25-056966Section “FURTHER INFORMATION REGARDING EXE CUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t20 · r10 · c17 · span 1018861–1018870
8Section 03, Caroline Baumal RSUDEF 14A2025-04-230000950170-25-056966Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r5 · c7 · span 849916–849922
9Section 03, David Watson RSUDEF 14A2025-04-230000950170-25-056966Section “FURTHER INFORMATION REGARDING EXE CUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t20 · r10 · c13 · span 1017595–1017604
10Section 03, Cedric Francois OPTIONDEF 14A2025-04-230000950170-25-056966Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r3 · c3 · span 843275–843282
11Section 03, Adam Townsend OPTIONDEF 14A2025-04-230000950170-25-056966Section “FURTHER INFORMATION REGARDING EXE CUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t20 · r13 · c17 · span 1045008–1045017
12Section 03, Cedric Francois RSUDEF 14A2025-04-230000950170-25-056966Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r3 · c7 · span 844443–844449
13Section 03, Timothy Sullivan RSUDEF 14A2025-04-230000950170-25-056966Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r4 · c7 · span 847180–847186
14Section 03, Adam Townsend RSUDEF 14A2025-04-230000950170-25-056966Section “FURTHER INFORMATION REGARDING EXE CUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t20 · r13 · c13 · span 1043742–1043751
15Section 03, Caroline Baumal OPTIONDEF 14A2025-04-230000950170-25-056966Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r5 · c3 · span 848749–848755
16Section 08, Gerald ChanDEF 14A2025-04-230000950170-25-056966Section “Director Compensation”. As printed: 498,715. Filing ↗machine: span 484609–484818
17Section 08, Alec MachielsDEF 14A2025-04-230000950170-25-056966Section “Director Compensation”. As printed: 492,465. Filing ↗machine: span 499827–500036
18Section 08, Paul FonteyneDEF 14A2025-04-230000950170-25-056966Section “Director Compensation”. As printed: 487,465. Filing ↗machine: span 494756–494965
19Section 08, Stephanie Monaghan O'BrienDEF 14A2025-04-230000950170-25-056966Section “Director Compensation”. As printed: 484,965. Filing ↗machine: span 504917–505126
20Section 08, A. Sinclair DunlopDEF 14A2025-04-230000950170-25-056966Section “Director Compensation”. As printed: 477,465. Filing ↗machine: span 489685–489894
21Section 08, Cedric FrancoisDEF 14A2025-04-230000950170-25-056966Section “Director Compensation”. As printed: 0. Filing ↗
22Section 08, Craig WheelerDEF 14A2025-04-230000950170-25-056966Section “Director Compensation”. As printed: —. Filing ↗
23Section 08, Keli WalbertDEF 14A2025-04-230000950170-25-056966Section “Director Compensation”. As printed: —. Filing ↗
24Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Craig Wheeler 2026-05-14Form 42026-05-140001193125-26-224585Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Keli Walbert 2026-05-14Form 42026-05-140001193125-26-224601Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Caroline Baumal 2026-05-14Form 42026-05-140001193125-26-224577Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Kelley Boucher 2026-05-14Form 42026-05-140001193125-26-224589Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Kelley Boucher 2026-05-14Form 42026-05-140001193125-26-224589Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Kelley Boucher 2026-05-14Form 42026-05-140001193125-26-224589Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Mark Jeffrey DeLong 2026-05-14Form 42026-05-140001193125-26-224597Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Keli Walbert 2026-05-14Form 42026-05-140001193125-26-224601Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Keli Walbert 2026-05-14Form 42026-05-140001193125-26-224601Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Keli Walbert 2026-05-14Form 42026-05-140001193125-26-224601Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Nur Nicholson 2026-05-14Form 42026-05-140001193125-26-224604Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Timothy Sullivan 2026-05-14Form 42026-05-140001193125-26-224615Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Paul Fonteyne 2026-05-14Form 42026-05-140001193125-26-224618Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Paul Fonteyne 2026-05-14Form 42026-05-140001193125-26-224618Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Paul Fonteyne 2026-05-14Form 42026-05-140001193125-26-224618Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Paul Fonteyne 2026-05-14Form 42026-05-140001193125-26-224618Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Paul Fonteyne 2026-05-14Form 42026-05-140001193125-26-224618Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Leslie Meltzer 2026-05-14Form 42026-05-140001193125-26-224620Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Leslie Meltzer 2026-05-14Form 42026-05-140001193125-26-224620Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Leslie Meltzer 2026-05-14Form 42026-05-140001193125-26-224620Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Mikael Dolsten 2026-05-14Form 42026-05-140001193125-26-224624Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, A. Sinclair Dunlop 2026-05-14Form 42026-05-140001193125-26-224633Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Craig Wheeler 2026-05-14Form 42026-05-140001193125-26-224585Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Caroline Baumal 2026-05-14Form 42026-05-140001193125-26-224577Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Pascal Deschatelets 2026-05-14Form 42026-05-140001193125-26-224609Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Leslie Meltzer 2026-05-14Form 42026-05-140001193125-26-224620Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Caroline Baumal 2026-05-14Form 42026-05-140001193125-26-224577Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Kelley Boucher 2026-05-14Form 42026-05-140001193125-26-224589Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, James George Chopas 2026-05-14Form 42026-05-140001193125-26-224627Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Caroline Baumal 2026-05-14Form 42026-05-140001193125-26-224577Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Caroline Baumal 2026-05-14Form 42026-05-140001193125-26-224577Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Caroline Baumal 2026-05-14Form 42026-05-140001193125-26-224577Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Caroline Baumal 2026-05-14Form 42026-05-140001193125-26-224577Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Caroline Baumal 2026-05-14Form 42026-05-140001193125-26-224577Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Caroline Baumal 2026-05-14Form 42026-05-140001193125-26-224577Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Keli Walbert 2026-05-14Form 42026-05-140001193125-26-224601Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Keli Walbert 2026-05-14Form 42026-05-140001193125-26-224601Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Alec Machiels 2026-05-14Form 42026-05-140001193125-26-224611Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, A. Sinclair Dunlop 2026-05-14Form 42026-05-140001193125-26-224633Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, A. Sinclair Dunlop 2026-05-14Form 42026-05-140001193125-26-224633Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, A. Sinclair Dunlop 2026-05-14Form 42026-05-140001193125-26-224633Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, A. Sinclair Dunlop 2026-05-14Form 42026-05-140001193125-26-224633Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, A. Sinclair Dunlop 2026-05-14Form 42026-05-140001193125-26-224633Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Paul Fonteyne 2026-05-14Form 42026-05-140001193125-26-224618Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Paul Fonteyne 2026-05-14Form 42026-05-140001193125-26-224618Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Stephanie Monaghan O'Brien 2026-05-14Form 42026-05-140001193125-26-224592Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, Cedric Francois 2026-05-14Form 42026-05-140001193125-26-224579Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
211Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
212Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
213Section 02, David Watson 2026-05-14Form 42026-05-140001193125-26-224583Insider equity transaction reported since the proxy statement. Filing ↗
214Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
215Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
216Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
217Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
218Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
219Section 02, Craig Wheeler 2026-05-14Form 42026-05-140001193125-26-224585Insider equity transaction reported since the proxy statement. Filing ↗
220Section 02, Craig Wheeler 2026-05-14Form 42026-05-140001193125-26-224585Insider equity transaction reported since the proxy statement. Filing ↗
221Section 02, Craig Wheeler 2026-05-14Form 42026-05-140001193125-26-224585Insider equity transaction reported since the proxy statement. Filing ↗
222Section 02, Gerald Chan 2026-05-14Form 42026-05-140001193125-26-224606Insider equity transaction reported since the proxy statement. Filing ↗
223Section 02, Kelley Boucher 2026-05-14Form 42026-05-140001193125-26-224589Insider equity transaction reported since the proxy statement. Filing ↗
224Section 06, 2025 voteForm 8-K2025-06-040001193125-25-134886Item 5.07 · say-on-pay result. As reported: 94.8% (votes for as printed: 75,901,920). Filing ↗
225Section 06, 2024 voteForm 8-K2024-06-050001193125-24-155179Item 5.07 · say-on-pay result. As reported: 89.88% (votes for as printed: 93,573,357). Filing ↗
226Section 06, 2023 voteForm 8-K2023-06-010001193125-23-158943Item 5.07 · say-on-pay result. As reported: 93.45% (votes for as printed: 94,979,579). Filing ↗
227Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
228Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
229Section 09b board cost (computed)Computed——Cash 441,250 + equity 999,960 + all other 0 = 1,441,210, summed across the director compensation table rows.machine: formula: Σ = 1,441,210
230PTC Therapeutics, Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗
231Madrigal Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-280001308179-26-000352CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952
232Corcept Therapeutics Incorporated, Section 10b CEO totalDEF 14A2026-04-170001628280-26-025735CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514
233Insmed Incorporated, Section 10b CEO totalDEF 14A2026-04-010001104506-26-000022CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563
234Blueprint Medicines Corporation, Section 10b CEO totalDEF 14A2025-04-240001558370-25-005415CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162
235Neurocrine Biosciences, Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
236Ionis Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗
237Biocryst Pharmaceuticals, Inc, Section 10b CEO totalDEF 14A2026-04-230001628280-26-026822CEO total compensation as printed in Biocryst Pharmaceuticals, Inc's own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266
238Apellis Pharmaceuticals, Inc. (subject), Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
239Axsome Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
240Intra-Cellular Therapies, Inc., Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
241Amicus Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
242ACADIA Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in ACADIA Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗
243Alkermes plc, Section 10b CEO totalDEF 14A2026-04-060001193125-26-143977CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267
244Section 10a, ACADIA Pharmaceuticals reciprocityDEF 14A—0001193125-26-174163ACADIA Pharmaceuticals names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
245Section 10a, Blueprint Medicines Corporation reciprocityDEF 14A—0001558370-25-005415Blueprint Medicines Corporation names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
246Section 10a, Madrigal Pharmaceuticals, Inc. reciprocityDEF 14A—0001308179-26-000352Madrigal Pharmaceuticals, Inc. names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
247Section 10a, Neurocrine Biosciences reciprocityDEF 14A—0000914475-26-000015Neurocrine Biosciences's most recent proxy was read; its disclosed peer group does not include Apellis Pharmaceuticals, Inc.. Filing ↗
248Section 10a, Amicus Therapeutics, Inc. reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics, Inc. names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
249Section 10a, PTC Therapeutics reciprocityDEF 14A—0001104659-26-045528PTC Therapeutics names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
250Section 10a, Axsome Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177610Axsome Therapeutics, Inc. names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
251Section 10a, Intra-Cellular Therapies, Inc. reciprocityDEF 14A—0001628280-24-018986Intra-Cellular Therapies, Inc. names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
252Section 10a, Biocryst Pharmaceuticals, Inc reciprocityDEF 14A—0001628280-26-026822Biocryst Pharmaceuticals, Inc names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
253Section 10a, Ionis Pharmaceuticals reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
254Section 10a, Insmed Incorporated reciprocityDEF 14A—0001104506-26-000022Insmed Incorporated's most recent proxy was read; its disclosed peer group does not include Apellis Pharmaceuticals, Inc.. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Apellis Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
APLS Peer Teardown Report